Table 2.
Number of patients at risk (%) for target non-attainment due to missing doses.
| Conventional Dosing | CYP2D6-Guided Dosing | MIPD (5.97 ng/mL Target) | MIPD (5.97 ng/mL Target) +10 mg |
MIPD (9 ng/mL Target) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Number of missed doses | 1 | 2 | 1 | 2 | 1 | 2 | 1 | 2 | 1 | 2 |
| Overall | 26.4 | 33.3 | 14.8 | 21.1 | 22.3 | 42.8 | 0.525 | 3.02 | 0.375 | 1.55 |
| gNM | 13.2 | 19.0 | 13.2 | 19.0 | 22.1 | 42.1 | 0.00 | 0.530 | 0.132 | 1.15 |
| gIM | 36.8 | 45.8 | 14.8 | 21.3 | 20.5 | 40.4 | 0.594 | 2.91 | 0.198 | 1.32 |
| gPM | 90.1 | 92.8 | 32.4 | 41.4 | 36.9 | 65.3 | 5.41 | 29.3 | 4.05 | 7.21 |
Abbreviations: gNM, gIM, and gPM: genotype-predicted normal, intermediate, and poor metabolisers, respectively. Bold: dosing strategies with lowest percentage of patients at risk having missed one or two doses, respectively.